chemotherapy cell histiocytosis improved by cladribine Progressive diffuse pulmonary Langerhans
نویسندگان
چکیده
UK and USA has serious side effects because of systemic dissemination of small particles. They omitted, however, an important experimental study which used larger talc particles (ie, the talc currently used in Europe for .70 years) and clearly showed that this talc does not disseminate in organs, unlike previous studies using American or Brazilian talc. This explains why many European respiratory physicians have used talc as a pleurodesing agent for .50 years without experiencing serious side effects. We thank the authors for referring to our European prospective study showing that talc poudrage under medical thoracoscopy is safe. There is, however, some misunderstanding of our results. In our paper we reported that we did not find any significant difference in oxygen saturation after the procedure. Physicians had a free choice of patient follow-up after thoracoscopy. There was, indeed, an increase in supplemental oxygen saturation, but we should not forget that routine use of oxygen by nasal prongs is often performed after thoracoscopy, as is done after many interventional procedures such as bronchoscopy. We agree that 7/558 patients developed radiographic pulmonary infiltrates after talc poudrage. However, this does not prove that talc was responsible for this rare infiltrate, which might have been the result of lung re-expansion after pleurodesis. On the other hand, we are not sure that control of the calibre of talc particles will increase the cost of graded talc. The current graded talc used in Europe since 1930 is safe, but has a unique drawback. It is very cheap and does not interest pharmaceutical companies because of the lack of potential for financial benefit. We agree that more research needs to be done into the mechanism of pleurodesis. However, in the meantime, the talc debate should be clarified; many patients suffering from lasting and severe dyspnoea related to malignant pleural effusion are relieved by thoracoscopic talc poudrage performed without intubation, under local anaesthesia with moderate sedation.
منابع مشابه
Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis
BACKGROUND Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disorder characterised by granulomatous proliferation of CD1a-positive histiocytes forming granulomas within lung parenchyma, in strong association with tobacco smoking, and which may result in chronic respiratory failure. Smoking cessation is considered to be critical in management, but has variable effects on outcome. No drug...
متن کاملEffect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis
Cladribine therapy may be beneficial in advanced forms of pulmonary Langerhans cell histiocytosis, even that with multiple cystic changes http://ow.ly/yeLr30i0Tt6.
متن کاملCladribine improves lung cysts and pulmonary function in a child with histiocytosis.
Langerhans’ cell histiocytosis (LCH) is a rare disease of unknown aetiology involving accumulation of Langerhans’ cell histiocytosis, organised in granuloma, in various organs [1]. Pulmonary LCH (PLCH), is characterised by focal Langerhans’ cell granulomas infiltrating and destroying distal bronchioles, which results in cysts, major destruction of the pulmonary tissue and pneumothorax [2, 3]. P...
متن کاملCladribine activity in adult langerhans-cell histiocytosis.
Langerhans-cell histiocytosis (LCH) results from the accumulation of tissue histiocytes derived from the same progenitor cells as monocytes. Because cladribine is potently toxic to monocytes, we conducted a phase II trial of cladribine. Cladribine was administered to 13 LCH patients at 0.14 mg/kg per day by 2-hour intravenous infusion for 5 consecutive days, every 4 weeks for a maximum of six c...
متن کاملSevere pulmonary hypertension in histiocytosis X: long-term improvement with bosentan.
Pulmonary Langerhans’ cell histiocytosis (LCH)/histiocytosis X is a rare smoking-related interstitial lung disease that predominantly affects adults aged 20–40 yrs. It is commonly associated with irreversible airflow obstruction and highly variable clinical outcomes. The disease may regress spontaneously or following smoking cessation; however, in 20–30% of cases it progresses to chronic respir...
متن کاملSuccessful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
INTRODUCTION Erdheim-Chester disease (ECD) is a rare, systemic form of non-Langerhans cell histiocytosis of the juvenile xanthogranuloma family with characteristic bilateral symmetrical long bone osteosclerosis, associated with xanthogranulomatous extra skeletal organ involvement. In ECD, central nervous system (CNS) and orbital lesions are frequent, and more than half of ECD pa tients carry th...
متن کامل